LPA and coronary artery disorder: Mendelian randomization analyses suggest that Lp(a) lowering of approximately a 65 mg/dL (Lamina et al., 2019) or 100 mg/dL (Emerging Risk Factors et al., 2009) (i.e., >150–200 nmol/dL) is required to achieve to CAD risk reduction equivalent of 1 mmol/L LDL-C lowering.